Premium
Desmoid tumor: A focus set on a challenging but understudied rare disease
Author(s) -
Kasper Bernd
Publication year - 2019
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.32119
Subject(s) - sorafenib , medicine , disease , autophagy , rare disease , oncology , cancer research , intensive care medicine , genetics , biology , apoptosis , hepatocellular carcinoma
This editorial highlights current developments and new paradigms in the management of desmoid tumor patients as developed by the Desmoid Tumor Working Group. The article “Autophagy Inhibition Overcomes Sorafenib Resistance in S45F‐Mutated Desmoid Tumors” is put into perspective regarding a new emerging drug, sorafenib, which is proven to be active in desmoid tumor in a recent phase 3 trial.